SARcode Bioscience eyes positive Phase III data for lead product
This article was originally published in Scrip
The privately held biopharmaceutical company SARcode Bioscience has reported positive top-line Phase III data for its lead product, lifitegrast (SAR 1118), showing that it significantly improved symptoms of dry eye, as well as corneal staining, a marker of ocular surface damage that is a hallmark of chronic inflammation from dry eye disease.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.